Early treatment with dapsone after spinal cord injury in rats decreases the inflammatory response and promotes long-term functional recovery

Calderón-Estrella, Francisco; Franco-Bourland, Rebecca E.; Rı́os, Camilo; Jesús-Nicolás, Diana de; Pineda, Benjamín; Méndez‐Armenta, Marisela; Mata-Bermúdez, Alfonso; Dı́az-Ruiz, Araceli

doi:10.1016/j.heliyon.2023.e14687

Search citation statements

Order By: Relevance

Paper Sections

Select...

The Antibiotic Dapsone1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dapsone suppresses IL-8 synthesis [143][144][145]. Dapsone also suppresses neutrophil chemotaxis to IL-8 gradients .…”

Section: The Antibiotic Dapsonementioning

confidence: 99%

The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive

Kast

2023

IJMS

View full text Add to dashboard Cite

As things stand in 2023, metastatic osteosarcoma commonly results in death. There has been little treatment progress in recent decades. To redress the poor prognosis of metastatic osteosarcoma, the present regimen, OSR9, uses nine already marketed drugs as adjuncts to current treatments. The nine drugs in OSR9 are: (1) the antinausea drug aprepitant, (2) the analgesic drug celecoxib, (3) the anti-malaria drug chloroquine, (4) the antibiotic dapsone, (5) the alcoholism treatment drug disulfiram, (6) the antifungal drug itraconazole, (7) the diabetes treatment drug linagliptin, (8) the hypertension drug propranolol, and (9) the psychiatric drug quetiapine. Although none are traditionally used to treat cancer, all nine have attributes that have been shown to inhibit growth-promoting physiological systems active in osteosarcoma. In their general medicinal uses, all nine drugs in OSR9 have low side-effect risks. The current paper reviews the collected data supporting the role of OSR9.

show abstract

“…Dapsone suppresses IL-8 synthesis [143][144][145]. Dapsone also suppresses neutrophil chemotaxis to IL-8 gradients .…”

Section: The Antibiotic Dapsonementioning

confidence: 99%

The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive

Kast

2023

IJMS

View full text Add to dashboard Cite

show abstract

Investigating the efficacy of dapsone in treating sepsis induced by cecal ligation and puncture surgery in male mice

Sayyad,

Dehpour,

Poopak

et al. 2024

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Early treatment with dapsone after spinal cord injury in rats decreases the inflammatory response and promotes long-term functional recovery

Cited by 2 publications

References 32 publications

The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive

The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive

Investigating the efficacy of dapsone in treating sepsis induced by cecal ligation and puncture surgery in male mice

Contact Info

Product

Resources

About